Ambrilia Biopharma Inc. (TSX:AMB) announce today that it is filing a final short form prospectus with securities regulatory authorities in British Columbia, Alberta, Manitoba, Ontario and Quebec in connection with its previously announced offering. This prospectus qualifies the distribution of 12,450,000 units of Ambrilia at a price of $1.25 per unit, for gross proceeds of $15.6 million. The offering is being underwritten by a syndicate of underwriters led by Canaccord Capital Corporation and which includes Dundee Securities Corporation and Loewen, Ondaatje, McCutcheon Limited. The issue price was determined by negotiation between the Company and the syndicate.
